Diagnostic performance of a doppler radar-based sleep apnoea testing device

Röcken, J., Darie, A.M., Grize, L. et al. BMC Pulm Med 25, 150 (2025). https://doi.org/10.1186/s12890-025-03618-9

Abstract

Background

Inpatient polysomnography (PSG) is the gold standard for the diagnosis of obstructive sleep apnoea (OSA), however, both complexity and costs limit the availability of this examination. Home sleep apnoea testing devices are a diagnostic alternative in patients with increased risk of OSA. We evaluated the diagnostic performance of a Doppler radar technology based, contactless sleep apnoea testing device (CSATD) in a cohort of patients with a clinically increased risk of OSA.

Methods

Monocentric prospective study. Sleep monitoring with the CSATD SleepizOne + without pulse oximetry (Sleepiz AG, Switzerland) was performed simultaneously with elective inpatient PSG. PSG was analysed blinded to the CSATD results and according to AASM 2012 criteria by certified sleep physicians. The CSATD data were analysed automatically and independently by a dedicated software.

Bibliometric and visual analysis of drug-specific immunotherapy from 1990 to 2024

Cui, Z., Chen, X., Zhai, S. et al.  Naunyn-Schmiedeberg's Arch Pharmacol (2025). https://doi.org/10.1007/s00210-025-04073-3

Abstract

Specific immunotherapy (SIT) is key in allergic diseases, tumor immunity, and autoimmune regulation. In recent years, the mechanism of action of drugs in SIT has attracted much attention, including the induction of hypersensitivity responses and modulation of immune tolerance. However, scientific challenges remain regarding their mechanism of action and optimization strategies. Studies on pharmacological SIT have been accumulated in the past, and there is an urgent need for bibliometric analyses to review and prospect these results for future academic development. Strict search criteria were developed to screen and download literature information from the Web of Science Core Collection.

Impact of allergic symptoms on work productivity in allergic rhinitis: A MASK-air direct patient data study

Vieira RJ, Pereira AM, Kupczyk M, Regateiro FS, Larenas-Linnemann DE, Toppila-Salmi S, Iinuma T, Kuna P, Cruz AA, Brussino L, Gemicioglu B, Samolinski B, Taborda-Barata L, Ventura MT, Kvedariene V, Klimek L, Pfaar O, Zuberbier T, Azevedo LF, Fonseca JA, Bousquet J, Sousa-Pinto B; MASK-air think tank. Allergol Int. 2025 Apr 1:S1323-8930(25)00002-4. doi: 10.1016/j.alit.2024.12.007. 

Abstract

Background: Allergic rhinitis may impair work productivity. This study aimed to assess (i) the differential impact of allergic rhinitis symptoms on work performance, assessed by means of Visual Analogue Scale (VAS) work; and (ii) the effect of asthma comorbidity on work productivity.

Methods: We assessed data from the MASK-air mHealth app of patients with allergic rhinitis. We identified factors associated with the impact of allergic symptoms on work productivity through multivariable linear mixed effects models.

Results: We studied 260,378 days from 20,724 patients. In multivariable regression models, nasal symptoms showed the strongest association with VAS work (regression coefficient = 0.38 [95%CI = 0.38; 0.38]). Poor rhinitis control, measured by the combined symptom-medication score, was associated with worse VAS work (regression coefficient = 0.96 [95%CI = 0.96; 0.97]). The median VAS work in patients with probable or possible asthma (median = 9, interquartile range = 22 for probable and 23 for possible asthma) was greater than for patients with no evidence of asthma (median = 3, interquartile range = 12) (Cohen's d = 0.60). In patients with probable asthma, nasal and asthma symptoms showed a similar impact on work productivity (regression coefficient for VAS nose = 0.32 [95%CI = 0.31; 0.32]; regression coefficient for VAS asthma = 0.30 [95%CI = 0.29; 0.31]).

Conclusions: Allergy symptoms, especially nasal symptoms, are associated with worse work productivity. In addition, patients with allergic rhinitis and asthma display more impairment in work productivity than patients with allergic rhinitis alone.

PDF

Pharmacokinetics and pharmacodynamics of neffy, epinephrine nasal spray, in pediatric allergy patients

Fleischer DM, Li HH, Talreja N et al. J Allergy Clin Immunol Pract. 2025 Mar 20:S2213-2198(25)00269-7. doi: 10.1016/j.jaip.2025.03.019.

Abstract

Background: Epinephrine is the gold-standard treatment for severe allergic reactions, including anaphylaxis and is typically administered via intramuscular injection. Despite epinephrine's well-documented safety and efficacy, patients may be hesitant to administer/receive injections, thereby increasing the risk of complications. neffy epinephrine nasal spray was developed to provide an additional option that may reduce dosing hesitancy.

Objective: This study was conducted to characterize neffy's pharmacokinetic and pharmacodynamic profiles in pediatric subjects, and to compare profiles between pediatric and adult subjects.

Hidden in plain sight: the impact of human rhinovirus infection in adults

Morelli, T., Freeman, A., Staples, K.J. et al. Respir Res 26, 120 (2025). https://doi.org/10.1186/s12931-025-03178-w

Abstract

Background

Impact of rhinovirus infection in adults

Human rhinovirus (HRV), a non-enveloped RNA virus, was first identified more than 70 years ago. It is highly infectious and easily transmitted through aerosols and direct contact. The advent of multiplex PCR has enhanced the detection of a diverse range of respiratory viruses, and HRV consistently ranks among the most prevalent respiratory pathogens globally. Circulation occurs throughout the year, with peak incidence in autumn and spring in temperate climates. Remarkably, during the SARS-CoV-2 pandemic, HRV transmission persisted, demonstrating its resistance to stringent public health measures aimed at curbing viral transmission.

Combination therapy blocking TNF superfamily members 14 and 15 reverses pulmonary fibrosis

Hope Steele, Ashley Willicut, Garrison Dell, Andrew Ghastine, Xinh-Xinh Nguyen, Paul Lembicz, Hailey Doerflein, Therese Suchoski, Elizabeth Kato, Carol Feghali-Bostwick, Michael Croft, Rana Herro, The Journal of Immunology, 2025;, vkaf002, https://doi.org/10.1093/jimmun/vkaf002

Abstract

Blocking LIGHT and TL1A in vivo protects against acute bleomycin-induced PF. 

Currently, anti-inflammatory drugs fail to reduce pulmonary fibrosis and tissue remodeling in the clinic. Thus, there is an unmet need to develop novel antifibrotic drugs capable of reversing disease. Our lab has identified two novel mediators of pulmonary fibrosis belonging to the tumor necrosis factor superfamily (TNFSF), LIGHT (TNFSF14) and TL1A (TNFSF15). Aside from their inflammatory roles, LIGHT and TL1A can directly activate structural cells involved in fibrosis, which express their receptors.

Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment

Zuraw, B.L., Bork, K., Bouillet, L. et al. Clinic Rev Allerg Immunol 68, 24 (2025). https://doi.org/10.1007/s12016-025-09027-4

Abstract

Hereditary angioedema (HAE) has been recognized for almost 150 years. The newest form of HAE, where C1 inhibitor levels are normal (HAE-nC1INH), was first described in 2000. Over the last two decades, new types of apparent non-mast cell–mediated angioedema with normal quantity and activity of C1INH have been described, in some cases with proven genetic pathogenic variants that co-segregate with angioedema expression within families. Like HAE due to C1INH deficiency, HAE-nC1INH patients are at risk of serious morbidity and mortality. Therefore, proactive management and treatment of HAE-nC1INH patients after an expert physician diagnosis is critically important.

Serum MRGPRX2 and substance P levels are biomarkers of disease activity rather than an antihistamine response in chronic spontaneous urticaria

Cuc, N.T.K., Minh, V.N., Lan, P.T. et al.  Sci Rep 15, 10014 (2025). https://doi.org/10.1038/s41598-025-94841-1

Abstract

In chronic spontaneous urticaria (CSU), the role of Mas-related G protein-coupled receptor X2 (MRGPRX2) and substance P (SP) as biomarkers of disease severity and the antihistamine response remains unclear. The study aims to examine the correlations between serum MRGPRX2 and SP levels, disease severity, and antihistamine response in patients with CSU. This study included 120 CSU patients and 30 healthy controls. Based on the Urticaria Activity Score over 7 days (UAS7), the patients with CSU were divided into two categories: severe (UAS7 ≥ 28) and non-severe (UAS7 < 28). Severe CSU patients received 20 mg of bilastine, titrated up to 80 mg based on Urticaria Control Test (UCT) results at days 15, 30, and 60. Serum MRGPRX2 and SP levels were measured at baseline for all participants and after two months in severe CSU patients.

Serum MRGPRX2 and SP concentrations between severe,
non-severe CSU and controls
(Kruskal-Wallis test with Dunn’s multiple comparison test). 

The Kruskal-Wallis test and Dunn’s corrections were used to examine differences in multiple comparisons.